Correlation Between LianBio ADR and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both LianBio ADR and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining LianBio ADR and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between LianBio ADR and Blueprint Medicines Corp, you can compare the effects of market volatilities on LianBio ADR and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in LianBio ADR with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of LianBio ADR and Blueprint Medicines.
Diversification Opportunities for LianBio ADR and Blueprint Medicines
-0.13 | Correlation Coefficient |
Good diversification
The 3 months correlation between LianBio and Blueprint is -0.13. Overlapping area represents the amount of risk that can be diversified away by holding LianBio ADR and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and LianBio ADR is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on LianBio ADR are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of LianBio ADR i.e., LianBio ADR and Blueprint Medicines go up and down completely randomly.
Pair Corralation between LianBio ADR and Blueprint Medicines
If you would invest 9,027 in Blueprint Medicines Corp on August 25, 2024 and sell it today you would earn a total of 388.00 from holding Blueprint Medicines Corp or generate 4.3% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 2.22% |
| Values | Daily Returns |
LianBio ADR vs. Blueprint Medicines Corp
Performance |
| Timeline |
| LianBio ADR |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Blueprint Medicines Corp |
LianBio ADR and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with LianBio ADR and Blueprint Medicines
The main advantage of trading using opposite LianBio ADR and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if LianBio ADR position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| LianBio ADR vs. Sensei Biotherapeutics | LianBio ADR vs. NextCure | LianBio ADR vs. Nuvation Bio | LianBio ADR vs. Inozyme Pharma |
| Blueprint Medicines vs. Eliem Therapeutics | Blueprint Medicines vs. HCW Biologics | Blueprint Medicines vs. Scpharmaceuticals | Blueprint Medicines vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |